DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Drug Profile

DPT-IPV-Hib vaccine - Mitsubishi Tanabe Pharma Corporation

Alternative Names: BK 1310

Latest Information Update: 19 Dec 2016

Price : $50

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation
  • Developer Mitsubishi Tanabe Pharma Corporation; Research Foundation for Microbial Diseases of Osaka University
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 01 Nov 2016 Phase-III clinical trials in Diphtheria (In infants, Prevention, In children) in Japan (SC)
  • 01 Nov 2016 Phase-III clinical trials in Haemophilus infections (Prevention, In infants, In children) in Japan (SC)
  • 01 Nov 2016 Phase-III clinical trials in Pertussis (Prevention, In infants, In children) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top